由美国制药公司礼来（Eli Lilly）生产的新型口服药物Foundayo（orforglipron）从周一起在英国药房开始销售1。英国由此成为欧洲首个批准该药物的国家1。这款药物用于治疗糖尿病患者，同时可辅助减肥1。
该药物适用于体重指数（BMI）≥30或BMI在27-30之间且至少患有一项与体重相关疾病的患者1。患者每天口服一次，服用不受进食或饮水影响1。初期阶段，该药物通过私人处方提供1，礼来公司正与英国健康与护理卓越研究所合作，评估将其纳入英国国家医疗服务体系（NHS）的可能性1。
国家药学协会首席执行官亨利·格雷格（Henry Gregg）表示，"这是第二种减肥药今天在特定药房上市的重要一天"1。与此同时，英国医学界面临假冒和未获许可GLP-1类减肥药物日益增多的问题1。英国药品和健康产品监管机构（MHRA）去年缴获了价值25万英镑的未获许可减肥笔和原料1。MHRA在6月份曾批准了第一种GLP-1减肥药Wegovy1。
A new oral medication called Foundayo (orforglipron), manufactured by American pharmaceutical company Eli Lilly, has begun selling in UK pharmacies as of Monday 1. The drug is designed to treat diabetes while simultaneously aiding weight loss, marking a significant expansion of treatment options in the country 1. The United Kingdom has become the first European nation to approve this medication 1.
The medicine is initially available through private prescriptions, with Eli Lilly currently working alongside the UK's National Institute for Health and Care Excellence to evaluate its potential inclusion within the NHS 1. Patients with a BMI of 30 or higher, or those with a BMI between 27 and 30 who have at least one weight-related condition, are eligible for the treatment 1. The drug is administered once daily by mouth and can be taken regardless of meal times 1. According to the National Pharmacy Association's chief executive, Henry Gregg, this represents "an important day with a second weight loss medicine launching in select pharmacies today" 1, following the MHRA's June approval of Wegovy, the first GLP-1 weight loss drug 1.
The launch comes amid growing concerns about counterfeit and unlicensed versions of GLP-1 medications circulating in the market 1. The MHRA seized unauthorized weight loss pens and raw materials valued at £250,000 last year 1, underscoring the regulatory challenges accompanying the increased demand for these treatments 1.
评论
还没有评论，欢迎留下第一条。